

## Epocal Completes \$31 million Series C Financing

Ottawa, Canada, April 10, 2007 - Epocal, a privately held developer of enterprise point-of-care blood diagnostic products, announces the closing of a US \$31 million Series C equity financing.

The Series C round was led by Highland Capital Management L.P. of Dallas, Texas and also included participation from founding investor, Genesys Capital Partners. Proceeds of the financing will be used to commercialize EPOCTM, the Company's FDA 510(k) approved blood diagnostic platform, as well as develop its proprietary immunoassay technology.

Epocal CEO Dr. Imants Lauks stated that "we are very excited to have a strong financial partner like Highland Capital Management join our investor group, and we are pleased to welcome Mr. Nathan Hukill of Highland Capital Management who joins Epocal's board of directors with the closing of this transaction."

Aquilo Partners Inc., a life science investment bank, was the exclusive placement agent for the transaction.